Baxter’s Foray Into CAR-T Cell Therapy With a Deal Worth US$ 1.7 B
By Taskin Ahmed & Rohit Khera
Pharma Deals Review: Vol 2016 Issue 3 (Table of Contents)
Published: 16 Mar-2016
DOI: 10.3833/pdr.v2016.i3.2147 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In its second deal in two months to bolster its immuno-oncology prospects, Baxalta has entered into a collaboration with Precision BioSciences to utilize the latter’s proprietary ARCUS genome editing technology to develop an allogeneic chimeric antigen receptor-T cell (CAR T) therapeutic pipeline directed towards areas of unmet need in multiple cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS